Erbitux Application For Type Of Lung Cancer Pulled
January 26th, 2009
ImClone Systems and Bristol-Myers Squibb Co. (BMY) withdrew their pending application for Erbitux to treat a type of lung cancer Friday after the Food and Drug Administration raised questions about potential differences between the product made in the U.S. and Europe.